Alkermes Response to Avadel Pharmaceuticals' Recent Announcement
Alkermes plc, a prominent biopharmaceutical company known for its innovative therapies, has taken notice of recent developments involving Avadel Pharmaceuticals plc. Following Avadel's recent statement suggesting a potential acquisition interest from H. Lundbeck A/S, this marks a crucial moment for both companies in the healthcare landscape.
Details of the Lundbeck Alternative Offer
In the announcement, Avadel indicated that a possible offer was made by Lundbeck to acquire all of its issued and outstanding ordinary shares. The board of Alkermes is actively evaluating the implications of this announcement, alongside their strategic advisors, to chart the right path forward.
Strategic Considerations for Alkermes
This development holds significant importance for Alkermes. The board is weighing its options regarding the future of its involvement with Avadel, taking into account the terms stipulated in the existing Transaction Agreement. According to these terms, Avadel cannot simply terminate the agreement to pursue a deal with Lundbeck unless certain conditions are met.
Implications of the Transaction Agreement
The Transaction Agreement outlines that Avadel must adhere to specific procedures if it seeks to entertain a Company Superior Proposal. This includes notifying Alkermes in writing five business days prior to any such action. Furthermore, it mandates that Avadel engage in good faith discussions with Alkermes regarding any potential amendments to the agreement.
Next Steps for Alkermes
Alkermes is committed to maintaining open lines of communication with Avadel throughout this evaluation process. As such matters unfold, further announcements will be made to provide stakeholders with timely updates.
Contact Information
The directors of Alkermes take responsibility for the information shared in this announcement. For inquiries, interested parties can reach out to the following contacts:
For Investors: Sandy Coombs
For Media: Katie Joyce
Telephone: +1 781 609 6377
Telephone: +1 781 249 8927
In addition, J.P. Morgan is acting as the financial advisor for Alkermes and will provide support throughout this critical period.
The company confirms that it will also publish additional information on its website, ensuring that all stakeholders stay informed on the next steps in this evolving situation.
Frequently Asked Questions
What is the recent announcement from Alkermes regarding Avadel?
Alkermes is responding to Avadel's announcement concerning a potential acquisition by Lundbeck and is reviewing its strategic options.
How is Alkermes involving its board in this process?
The board is closely evaluating the implications of the announcement and seeking guidance from its advisors.
What is the importance of the Transaction Agreement?
The Transaction Agreement sets forth specific terms that Avadel must follow if it wishes to enter into an agreement with Lundbeck, ensuring due diligence is observed.
Who should be contacted for more information?
Interested parties can contact Sandy Coombs for investor inquiries and Katie Joyce for media inquiries regarding Alkermes.
What will happen next regarding this potential acquisition?
Alkermes will provide further updates as developments occur, ensuring stakeholders are kept well-informed throughout this process.
